Review: Postprandial glycaemia and cardiovascular risk

Abstract

Cardiovascular disease (CVD) accounts for almost 75% of mortality in subjects with type 2 diabetes. There is emerging evidence (epidemiological and There is emerging evidence (epidemiological and experimental studies) that postprandial glucose (PPG) contributes significantly to CVD risk, although to date there are no large scale interventional studies with the primary objective of reducing cardiovascular complications by targeting PPG. There is still continuing debate about the definition of postprandial hyperglycaemia. Moreover, we now know more of the cellular mechanisms being triggered in response to glucose excursions which may offer an explanation to this increased susceptibility to CVD. The contribution of PPG to glycosylated haemoglobin, is predominant in relatively well controlled subjects with type 2 diabetes. Hence, PPG is emerging as a legitimate therapeutic target to minimise CVD risk.

This review looks at the evidence linking postprandial hyperglycaemia to CVD, the cellular mechanisms explaining this enhanced risk and a therapeutic strategy to address PPG.

Keywords

all-cause mortality cardiovascular disease cellular mechanism diabetes postprandial glucose postprandial hyperglycaemia.

Get full access to this article

View all access options for this article.

References

Weir GC , Leahy JL Joslin's diabetes mellitus. 13th edn. Lea and Febiger. Philadelphia, PA , 1994.

Bogardus C. Diabetes Mellitus. Lippincot-Raven Publishers. Philadelphia, PA, 1996.

DeFronzo RA Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667-87.

Monnier L.

Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes?

E J Clin Invest 2000;30:(suppl 2);3-11.

Monnier L. , Colette C. , Dunseath GJ , Owens DR The loss of postprandial glycaemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007;30:263-9.

American Diabetes Association. Postprandial blood glucose. American Diabetes Association. Diabetes Care 2001;24:775-8.

American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. Endocrine Practice 2002 ;8(suppl 1):5-11.

European Diabetes Policy Group 1999. A desktop guide to Type 2 diabetes mellitus. Diabetic Medicine 1999;16:716-30.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

10.

Stratton IM , Adler AI , Neil HAW et al. the UK Prospective Diabetes Study Group : Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.

11.

The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.

12.

Shichiri M. , Kishikawa H. , Ohkubo Y. et al. Long term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients . Diabetes Care 2000;23:B21-B9.

13.

Wolever TMS , Chiasson JL , Csima A. et al. Variation of postprandial plasma glucose, palatability and symptoms associated with a standardized mixed test meal versus 75 g oral glucose. Diabetes Care 1998;21:336-40.

14.

Coutinho M. , Gerstein HC , Wang Y. et al. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-40.

15.

DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2 hour diagnostic criteria. Arch Intern Med 2001;161:397-405.

16.

de Vegt F. , Dekker JM , Ruhe HG et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-31.

17.

Donahue RP , Abbott RD , Reed DM et al. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes 1987;36:689-92.

18.

Lowe LP , Liu K. , Greenland P. et al. Diabetes, asymptomatic hyperglycaemia, and 22 year mortality in black and white men: the Chicago Heart Association Detection Project in Industry study. Diabetes Care 1997;20:163-9.

19.

Hanefeld M. , Fischer S. , Julius U. et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11 year follow-up. Diabetologia 1996;39:1577-83.

20.

Pyorala K. , Savolainen E. , Lehtovirta E. et al. Glucose tolerance and coronary heart disease: Helsinki policeman study. J Chronic D 1979;32:729-45.

21.

Balkau B. , Pyorala M. , Shipley M. et al. High blood glucose concentration is a risk factor for mortality in middle aged non-diabetic men. 20 year follow-up to the Whitehall Study, the Paris Prospective Study and the Helsinki Policeman Study. Diabetes Care 1998;21:360-7.

22.

Jackson CA , Yudkin JS , Forrest RD A comparison of the relationships of the glucose tolerance test and the glycated haemoglobin assay with diabetic vascular disease in the community. The Islington Diabetes survey. Diabetes Res Clin Pract 1992 ;17:111-23.

23.

Barrett-Connor E. , Ferrara A. Isolated post challenge hyperglycaemia and the risk of fatal cardiovascular disease in older women and men. Diabetes Care 1998;21:1236-9.

24.

Shaw JE , Hodge AM , Courten M. et al. Isolated post-challenge hyperglycaemia confirmrd as a risk. Diabetologia 1999;42:1050-4.

25.

Meigs JB , Nathan DM , D'Agostino RB et al. Fasting and post-challenge glycaemia and cardiovascular disease risk: The Framingham Offspring Study. Diabetes Care 2002;25:1845-50.

26.

Tominaga M. , Igarashi K. , Eguchi H. et al. Impaired glucose tolerance is a risk factor for cardiovascular disease but not impaired fasting glucose. Diabetes Care 1999;22:920-4.

27.

Barzilay JI , Spiekerman CF , Wahl PW et al. Cardiovascular disease in older adults with glucose disorders: a comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 1999;354:622-5.

28.

Saydah SH , Loria CM , Eberhardt MS et al. Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care 2001;24:447-53.

29.

Salonen JT , Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 1991;11:1245-49.

30.

Heiss G. , Sharett AR , Barnes R. et al. Carotid atherosclerosis measured by B-mode ultrasound in populations: association with cardio-vascular risk factors in the ARIC Study. Am J Epidemiol 1991;134:250-6.

31.

Hanefeld M. , Koehler C. , Henkel E. et al. Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intimamedia thickness: The RIAD Study. Risk factors in impaired glucose tolerance for atherosclerosis and diabetes. Diabetic Medicine 2000;17:835-40.

32.

Temelkova-Kurktschiev T. , Koehler C. , Schaper F. et al. Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals. Diabetologia 1998 ;41:706-12.

33.

Chiasson JL , Josse RG , Gomis R. et al. STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial . Lancet 2002;359:2072-7.

34.

Chiasson JL , Josse RG , Gomis R. et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003 ;290:486-94.

35.

Hanefeld M. , Chiasson JL , Koehler C. et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance . Stroke 2004 ;35:1073-8.

36.

Esposito K. , Giugliano D. , Nappo F. et al. Regression of carotid atherosclerosis by control of postprandial hyperglycaemia in type 2 diabetes mellitus. Circulation 2004;29:2978-84.

37.

Teno S. , Uto Y. , Nagashima H. et al. Association of postprandial hypertriglyceridaemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care 2000;23:1401-06.

38.

Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.

39.

Pieper GM , Langenstroer P. , Siebeneich W. Diabetic induced endothelial dysfunction in rat aorta: role of hydroxy radicals . Cardiovascular Research 1997;34:145-56.

40.

Garcia SF , Virag L. , Jagtap P. et al. Diabetic endothelial dysfunction: the role of poly (ADP-ribose) polymerase activation. Nature Medicine 2001 ;7:108-13.

41.

Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005:54:1615-25.

42.

Du XL , Edelstein D. , Rossetti L. et al. Hyperglycaemia induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 2000;97:12222-6.

43.

Tsai EC , Hirsch IB , Brunzell JD et al. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 1994;43:1010-14.

44.

Diwadkar VA , Anderson JW , Bridges SR et al. Postprandial low density lipoproteins in type 2 diabetes are oxidised more extensively than fasting diabetes and control samples. Proc Soc Exp Biol Med 1999 ;222:178-84.

45.

Ceriello A. , Bortolotti N. , Motz E. et al. Meal induced oxidative stress and low density lipoprotein oxidation in diabetes: the possible role of hyperglycaemia . Metabolism 1999;48:1503-08.

46.

Kawano H. , Motoyama T. , Hirashima O. et al. Hyperglycaemia rapidly suppresses flow mediated endothelium dependant vasodilation of brachial artery. J Am Coll Cardiol 1999;34:146-54.

47.

Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993 ; 36:1119-25.

48.

Nappo F. , Esposito K. , Cioffi M. et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 2002;39:1145-50.

49.

Dekker JM , Schouten EG , Klootwijk P. et al. Association between QT interval and coronary heart disease in middle-aged and elderly men. The Zutphen Study. Circulation 1994;90:779-85.

50.

Marfella R. , Nappo F. , De Angelis L. et al. The effect of acute hyperglycaemia on QTc duration in healthy man. Diabetologia 2000;43:571-75.

51.

Monnier L. , Lapinski H. , Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients. Diabetes Care 2003;26:881-5.

52.

Peter R. , Luzio SD , Dunseath G. et al. Relationship between HbA1c and indices of glucose tolerance derived from a standardized meal test in newly diagnosed treatment naïve subjects with type 2 diabetes. Diabetic Medicine 2006 ;23:990-5.

53.

Owens DR , Dolben J. , Jones IR et al. Hormonal and glycaemic responses to serial meals in newly diagnosed non-insulin dependant diabetic patients. Diabetes & Metabolism 1989;15:1-4.

54.

Dunseath G. , Peter R. , Chudleigh R. et al. Contribution of postprandial and fasting plasma glucose to each of 3 identical meals during the day and also to diurnal hyperglycaemia in persons with type 2 diabetes . Diabetes 2007;56(suppl 1):2692PO.

55.

Gaede P. , Vedel P. , Larsen N. , Jensen GV , Parving HH , Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. NEJM 2003;348:383-93.

56.

Kado S. , Muramaki T. , Aoki A. et al. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diabetes Res Clin Pract 1998;41:49-55.

57.

De Veciana M. , Major CA , Morgan MA et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995; 333:1237-41.